Titre : Composant-7 du complexe de maintenance des minichromosomes

Composant-7 du complexe de maintenance des minichromosomes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Core Binding Factor Alpha 2 Subunit
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Composant-7 du complexe de maintenance des minichromosomes : Questions médicales les plus fréquentes", "headline": "Composant-7 du complexe de maintenance des minichromosomes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Composant-7 du complexe de maintenance des minichromosomes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-23", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Composant-7 du complexe de maintenance des minichromosomes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines de maintenance des minichromosomes", "url": "https://questionsmedicales.fr/mesh/D064110", "about": { "@type": "MedicalCondition", "name": "Protéines de maintenance des minichromosomes", "code": { "@type": "MedicalCode", "code": "D064110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.235.750" } } }, "about": { "@type": "MedicalCondition", "name": "Composant-7 du complexe de maintenance des minichromosomes", "alternateName": "Minichromosome Maintenance Complex Component 7", "code": { "@type": "MedicalCode", "code": "D064168", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Qing Yang", "url": "https://questionsmedicales.fr/author/Qing%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China." } }, { "@type": "Person", "name": "Binhui Xie", "url": "https://questionsmedicales.fr/author/Binhui%20Xie", "affiliation": { "@type": "Organization", "name": "Department of Hepatobiliary Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China." } }, { "@type": "Person", "name": "Hui Tang", "url": "https://questionsmedicales.fr/author/Hui%20Tang", "affiliation": { "@type": "Organization", "name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China." } }, { "@type": "Person", "name": "Wei Meng", "url": "https://questionsmedicales.fr/author/Wei%20Meng", "affiliation": { "@type": "Organization", "name": "Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China." } }, { "@type": "Person", "name": "Changchang Jia", "url": "https://questionsmedicales.fr/author/Changchang%20Jia", "affiliation": { "@type": "Organization", "name": "Cell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma.", "datePublished": "2024-02-29", "url": "https://questionsmedicales.fr/article/38468936", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.heliyon.2024.e27191" } }, { "@type": "ScholarlyArticle", "name": "The E3 ligase DTX2 inhibits RUNX1 function by binding its C terminus and prevents the growth of RUNX1-dependent leukemia cells.", "datePublished": "2023-08-23", "url": "https://questionsmedicales.fr/article/37500075", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/febs.16914" } }, { "@type": "ScholarlyArticle", "name": "Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.", "datePublished": "2023-12-07", "url": "https://questionsmedicales.fr/article/38062912", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.6693" } }, { "@type": "ScholarlyArticle", "name": "Circ_0004491 stimulates guanine nucleotide-binding protein alpha subunit to inhibit the malignant progression of oral squamous cell carcinoma by sponging miR-2278.", "datePublished": "2022-06-15", "url": "https://questionsmedicales.fr/article/36643221", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jds.2022.05.018" } }, { "@type": "ScholarlyArticle", "name": "Disordered-to-ordered transitions in assembly factors allow the complex II catalytic subunit to switch binding partners.", "datePublished": "2024-01-11", "url": "https://questionsmedicales.fr/article/38212624", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-44563-7" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Nucléoprotéines", "item": "https://questionsmedicales.fr/mesh/D009698" }, { "@type": "ListItem", "position": 5, "name": "Protéines chromosomiques nonhistones", "item": "https://questionsmedicales.fr/mesh/D002868" }, { "@type": "ListItem", "position": 6, "name": "Protéines de maintenance des minichromosomes", "item": "https://questionsmedicales.fr/mesh/D064110" }, { "@type": "ListItem", "position": 7, "name": "Composant-7 du complexe de maintenance des minichromosomes", "item": "https://questionsmedicales.fr/mesh/D064168" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Composant-7 du complexe de maintenance des minichromosomes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Comment diagnostiquer une anomalie du Composant-7 ?\nQuels tests sont utilisés pour évaluer le Composant-7 ?\nY a-t-il des marqueurs spécifiques pour le Composant-7 ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le Composant-7 ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Quels sont les symptômes d'une défaillance du Composant-7 ?\nPeut-on observer des symptômes cliniques ?\nLes symptômes varient-ils selon les individus ?\nY a-t-il des signes précoces d'anomalies ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Peut-on prévenir les anomalies du Composant-7 ?\nY a-t-il des facteurs environnementaux à éviter ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes vaccinations peuvent-elles aider ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?\nLa thérapie génique est-elle efficace ?\nDes médicaments spécifiques sont-ils utilisés ?\nLe traitement nécessite-t-il une surveillance régulière ?\nY a-t-il des effets secondaires aux traitements ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?\nLes anomalies peuvent-elles affecter la fertilité ?\nY a-t-il des risques de maladies associées ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Composant-7 du complexe de maintenance des minichromosomes", "description": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?\nL'âge influence-t-il le risque d'anomalies ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des antécédents familiaux à considérer ?\nLes infections pendant la grossesse sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D064168?mesh_terms=Core+Binding+Factor+Alpha+2+Subunit&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie du Composant-7 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de protéines peuvent identifier des anomalies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le Composant-7 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de Western blot et les analyses de PCR sont couramment utilisés." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour le Composant-7 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs protéiques spécifiques peuvent indiquer des dysfonctionnements." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être nécessaire pour des analyses plus approfondies." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec le Composant-7 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la division cellulaire peuvent être des indicateurs." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une défaillance du Composant-7 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles de la division cellulaire et des anomalies chromosomiques." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cliniques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes cliniques peuvent apparaître, mais ils sont souvent non spécifiques." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les individus ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la gravité de l'anomalie." } }, { "@type": "Question", "name": "Y a-t-il des signes précoces d'anomalies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes précoces peuvent inclure des retards de croissance cellulaire." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies du Composant-7 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut aider." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les toxines et les radiations peut réduire les risques d'anomalies." } }, { "@type": "Question", "name": "Des dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages réguliers peuvent aider à détecter des anomalies précocement." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la santé cellulaire et réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui affectent la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies du Composant-7 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent inclure des thérapies géniques et des médicaments ciblés." } }, { "@type": "Question", "name": "La thérapie génique est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique montre des résultats prometteurs dans certains cas." } }, { "@type": "Question", "name": "Des médicaments spécifiques sont-ils utilisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques peuvent être utilisés pour cibler les anomalies." } }, { "@type": "Question", "name": "Le traitement nécessite-t-il une surveillance régulière ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surveillance régulière est essentielle pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires peuvent survenir, nécessitant une gestion attentive." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies du Composant-7 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers et des troubles génétiques." } }, { "@type": "Question", "name": "Les anomalies peuvent-elles affecter la fertilité ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies peuvent entraîner des problèmes de fertilité." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des risques accrus de maladies métaboliques peuvent être observés." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles." } }, { "@type": "Question", "name": "Comment les complications sont-elles traitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement des complications dépend de leur nature et de leur gravité." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies du Composant-7 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé peut augmenter le risque d'anomalies chromosomiques." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie malsain peut augmenter le risque d'anomalies génétiques." } }, { "@type": "Question", "name": "Y a-t-il des antécédents familiaux à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les infections pendant la grossesse sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections pendant la grossesse peuvent affecter le développement chromosomique." } } ] } ] }

Sources (10000 au total)

Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma.

This study aims to explore the clinical value of P4HA2 (prolyl 4-hydroxylase subunit alpha 2) in Osteosarcoma (OSC), and assess its potential to provide directions and clues for the practice of precis... The GSE73166 and GSE16088 datasets were used to explore the P4HA2 expression in OSC. We then used the clinical data of patients obtaining from TARGET database to assess the prognostic value of P4HA2 i... The P4HA2 mRNA expression was higher in OSC than that in normal tissues and other bone cancer samples. Survival analysis found that P4HA2 high expression caused poor overall survival (OS) of patients ... This study revealed that P4HA2 can serve as an important prognostic biomarker for OSC patients, and it may become a promising therapeutic target in OSC treatment....

Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.

Chromosomal translocations involving core binding factor (CBF) genes account for 15% of adult acute myeloid leukemia (AML) cases in China. Despite being classified as favorable-risk by European Leukem... Retrospective analysis of 149 AML patients (75 CBF-AML, 74 non-CBF) at Peking University First Hospital (March 2012-March 2022).... CBF-AML patients have significantly lower disease-free survival (DFS) (p = 0.005) and higher non-relapse mortality (NRM) (p = 0.028) compared to non-CBF AML. inv (16) and t(8;21) show distinct co-occu... Prognosis of CBF-AML is poorer than ELN guidelines suggest. inv(16) and (8;21) are separate entities with relatively poor prognoses, requiring rational risk stratification strategies. Allo-HSCT may be...

Circ_0004491 stimulates guanine nucleotide-binding protein alpha subunit to inhibit the malignant progression of oral squamous cell carcinoma by sponging miR-2278.

Circular RNA origin recognition complex subunit 4 (circORC4; ID: hsa_circ_0004491) have been confirmed to be a novel potential biomarker of oral squamous cell carcinoma (OSCC). This study aimed to exp... Levels of circ_0004491, microRNA (miR)-2278, guanine nucleotide-binding protein alpha subunit (GNAS), Bax, Bcl-2, E-cadherin and ki-67 were detected by quantitative real-time PCR, western blotting and... Circ_0004491 was downregulated in OSCC tissues and cell lines. Circ_0004491 overexpression suppressed the proliferation, migration and invasion whereas facilitated the apoptosis of OSCC cells. Circ_00... Circ_0004491 can repress OSCC progression by regulation of miR-2278/GNAS axis, providing a possible circRNA-targeted therapy for OSCC....

Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners.

The factor XIII (FXIII)-B subunit has a critical function as a carrier protein to stabilize FXIII-A in plasma and supply it to its main substrate, fibrinogen. However, the function of the excess free ... In the present study, we explored potential interactions of free FXIII-B with complement factors and searched for novel binding partners.... We tested for cofactor activity in the degradation of complement C3b and C4b and used ELISA- and surface plasmon resonance-based binding assays to investigate interactions between FXIII-B and compleme... FXIII-B did not exhibit cofactor activity in the degradation of C3b and C4b similar to factor H and C4b-binding protein, nor did it bind to complement factors to a relevant extent. Identification of p... Our study reveals that free FXIII-B has no direct role in regulating the complement system, despite a structural similarity to major complement regulators. Further studies are needed to validate α2MG ...